Plosaracetam (INNTooltip International Nonproprietary Name; developmental code names ABBV-552, SDI-118) is a synaptic vesicle glycoprotein 2A (SV2A) ligand which is under development for the treatment of Alzheimer's disease and other cognition disorders.

[1][3][4][2] In contrast to earlier SV2A ligands like levetiracetam and brivaracetam, polsaracetam does not have anticonvulsant activity and instead shows pro-cognitive effects.

[2] The drug is being developed by UCB Biopharma and AbbVie.

[1][3] As of October 2024, it is in phase 2 clinical trials for Alzheimer's disease and phase 1 trials for cognition disorders.

[1][3] This drug article relating to the nervous system is a stub.